Clinical Trials | April 16, 2024
Novartis reports data from trial of IgA nephropathy treatment
IgAN is a heterogeneous, progressive, rare kidney disease and is a major cause of chronic kidney disease worldwide
IgAN is a heterogeneous, progressive, rare kidney disease and is a major cause of chronic kidney disease worldwide
The period from 2020 to 2022 witnessed a remarkable surge in deal worth
A significant proportion of healthcare professionals still tend to favor branded drugs
The approval marks a significant milestone for the American pharmaceutical company in the field of UC
The FDA assigned a Prescription Drug User Fee Act (PDUFA) goal date of June 21, 2024
The report underscores significant advancements in healthcare delivery, showcasing how GenAI facilitates improved diagnostic accuracy, operational efficiency and patient engagement
The U.S. FDA recently approved Xolair as the first and only medicine for children and adults with one or more food allergies
The three-day forum will feature global leaders, scientists, regulatory body representatives, industry associations, and academia among many others
The survey data presented in “The State of the Biopharmaceutical Industry 2024” report reveals that N=21 (18%) of industry professionals were convinced that CGT will dominate as the most important trend in pharma next year
Leading USA based genetic testing brand officially enters the Indian market
Subscribe To Our Newsletter & Stay Updated
